High-yield white blood cell preparation collected by continuous-flow apheresis over 3–5 hours. A single leukopak yields 5–20 billion leukocytes — 50–100× more than standard venipuncture. The gold standard starting material for cell therapy manufacturing.
A leukopak (also called a leukapheresis product) is a concentrated white blood cell preparation collected using a continuous-flow apheresis machine. During the 3–5 hour procedure, the donor's blood is drawn, centrifuged to separate leukocytes from plasma and red cells, and then the red cells and plasma are returned to the donor. The collected leukocyte fraction — typically 200–400 mL — is the leukopak product.
The procedure is performed at an accredited apheresis center under FDA-registered protocols. ACD-A (acid citrate dextrose formula A) is the standard anticoagulant used during collection. The resulting product contains all circulating leukocyte subtypes — T cells, B cells, NK cells, monocytes, and granulocytes — at a concentration roughly 40–80× higher than whole blood.
When you buy a leukopak for research, the practical advantage is scale. A single unit provides enough starting material for CAR-T manufacturing runs, multi-arm functional studies, scRNA-seq with rare cell populations, or PBMC banking across dozens of downstream experiments — all from a single, fully consented, AI-matched donor.
| Parameter | Detail |
|---|---|
| Product Volume | ~200–400 mL per unit (apheresis center dependent) |
| Total WBC Yield | 5–20 × 10⁹ leukocytes per unit (donor-variable) |
| Anticoagulant | ACD-A (acid citrate dextrose formula A) |
| Collection Procedure | Continuous-flow leukapheresis, 3–5 hours, performed at accredited apheresis center |
| Donor Interval | Every 4–8 weeks per FDA/AABB guidelines |
| Storage | Processed same day; PBMC fraction stored at -150°C to -196°C in LN₂ vapor phase |
| Testing | Infectious disease testing (HIV, HBV, HCV, CMV, syphilis) available; NAT testing on request |
| Documentation | Full apheresis collection record, donor medical history, demographics, IRB consent, QC viability |
Provide target cell yield, required donor criteria (demographics, disease state, HLA type, CMV status, ID testing panel), downstream application, and delivery timeline.
We identify matched donors from our pool, confirm eligibility with the apheresis center, and schedule collection. Lead time is typically 1–2 weeks for standard collections.
Leukopak is collected and shipped same day in an insulated container with wet ice. Full collection documentation, viability data, and ID testing results are included.
A standard leukopak (approximately 200 mL product volume) typically yields 5–20 × 10⁹ total leukocytes. After Ficoll PBMC isolation, expect 2–10 × 10⁹ PBMCs — compared to 30–180 × 10⁶ from a standard 30 mL venipuncture. This is a 50–100× increase in PBMC yield per donor, making leukopaks essential for cell therapy manufacturing and large-scale functional studies.
FDA regulations and standard apheresis protocols allow collection every 4–8 weeks, depending on WBC recovery monitoring. Leukocyte counts return to baseline within 48–72 hours for most donors. We maintain longitudinal donor relationships and can schedule repeat collections from the same donor for matched temporal studies.
A leukopak is collected by continuous-flow apheresis over 3–5 hours, processing the entire circulating blood volume to selectively enrich leukocytes. A buffy coat is the thin WBC layer manually extracted from a single centrifuged blood tube. Leukopaks yield 50–100× more cells per donor at higher purity and with less red cell contamination. The tradeoff is cost and donor procedure time.
Submit your cell yield and donor criteria to receive a quote within 24 hours.
Request Leukopak